Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972-1980

Diabetes Care. 2017 Jun;40(6):809. doi: 10.2337/dc17-er06d. Epub 2017 Apr 20.
No abstract available

Publication types

  • Published Erratum